SINGLE AGENT EPIRUBICIN VERSUS THE COMBINATION EPIRUBICIN PLUS TAMOXIFEN AS PRIMARY CHEMOTHERAPY IN BREAST CANCER PATIENTS. A SINGLE INSTITUTION PHASE III TRIAL


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles